Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2020-02-14 12:01 pm Sale | 13G | ESSA PHARMA INC EPIX | Omega Fund IV L.P. | 1,782,151 8.6% | -20,520,878 (-92.01%) | View |
| 2020-02-12 4:03 pm Sale | 13G | ESSA PHARMA INC EPIX | Soleus Capital LLC | 2,122,973 9.99% | -15,289 (-0.72%) | View |
| 2020-02-04 3:47 pm Purchase | 13G | ESSA PHARMA INC EPIX | EVENTIDE ASSET MANAGEMENT LLC | 2,010,169 9.7% | 1 (+0.00%) | View |
| 2019-11-12 2:31 pm Purchase | 13G | ESSA PHARMA INC EPIX | ORBIMED ADVISORS LLC | 1,471,853 7.1% | 1,471,853 (New Position) | View |
| 2019-09-06 5:22 pm Purchase | 13D | ESSA PHARMA INC EPIX | Clarus Lifesciences III L.P. | 3,479,114 16.7% | 1,704,493 (+96.05%) | View |
| 2019-08-30 3:31 pm Purchase | 13G | ESSA PHARMA INC EPIX | EVENTIDE ASSET MANAGEMENT LLC | 2,010,168 9.68% | 625,000 (+45.12%) | View |
| 2019-08-29 09:44 am Purchase | 13G | ESSA PHARMA INC EPIX | Soleus Capital LLC | 2,138,262 9.99% | 2,138,262 (New Position) | View |
| 2019-07-15 09:50 am Sale | 13D | ESSA PHARMA INC EPIX | EVENTIDE ASSET MANAGEMENT LLC | 1,385,168 17.4% | -802 (-0.06%) | View |
| 2019-06-27 6:06 pm Purchase | 13G | ESSA PHARMA INC EPIX | BIOTECHNOLOGY VALUE FUND L P | 1,329,700 16.7% | 749,333 (+129.11%) | View |
| 2019-05-23 11:44 am Unchanged | 13D | ESSA PHARMA INC EPIX | EVENTIDE ASSET MANAGEMENT LLC | 1,385,970 19.2% | 0 (Unchanged) | View |